56 Participants Needed

SRP-3D for Pain Management

SM
Overseen ByStudy Manager
Age: 18 - 65
Sex: Any
Trial Phase: Phase 1
Sponsor: South Rampart Pharma, LLC

Trial Summary

What is the purpose of this trial?

This trial tests a new drug called SRP-3D (DA) in a general study group. It aims to gather information on safety and how the drug behaves in the body.

Will I have to stop taking my current medications?

Yes, participants must stop taking any prescribed or over-the-counter drugs to be eligible for this trial.

How does the drug SRP-3D differ from other pain management drugs?

The drug SRP-3D (diethylamide) is unique because it may involve a novel mechanism of action or administration route compared to standard opioid treatments, which typically target specific opioid receptors like mu and delta. While the research does not directly mention SRP-3D, it highlights the potential for new opioid compounds like AM 94, which have shown greater and longer-lasting pain relief in animal studies, suggesting SRP-3D might offer similar innovative benefits.12345

Research Team

HA

Hernan A Bazan, MD

Principal Investigator

CEO

Eligibility Criteria

This trial is for healthy men and women aged 18-55 who are not pregnant or breastfeeding. Participants must understand English or Spanish, have a BMI of 18-32, agree to use birth control if applicable, and commit to the study schedule including inpatient stays and outpatient visits.

Inclusion Criteria

Your basic body measurements are within normal ranges.
I agree to stay in the hospital when needed and come back for follow-up visits.
You are a healthy man or woman who is not pregnant or breastfeeding.
See 6 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

SAD (Single Ascending Dose) Assessment

Participants receive single ascending doses of SRP-3D (DA) to assess safety and pharmacokinetics, including a food effect assessment

6 days

MAD (Multiple Ascending Dose) Assessment

Participants receive multiple ascending doses of SRP-3D (DA) to assess safety and pharmacokinetics

6 days

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

  • Placebo
  • SRP-3D (diethylamide)
Trial Overview The study tests SRP-3D (diethylamide), a new drug for pain relief. It's compared with a placebo in two parts: single ascending dose (SAD) and multiple ascending dose (MAD). The process is randomized and double-blind, meaning neither participants nor researchers know who gets the real drug.
Participant Groups
2Treatment groups
Experimental Treatment
Placebo Group
Group I: ExperimentalExperimental Treatment1 Intervention
SRP-3D (Diethylamide) Oral Suspension, 100 mg/mL
Group II: PlaceboPlacebo Group1 Intervention
Matching Placebo for SRP-3D (Diethylamide) Oral Suspension, 100 mg/mL

Find a Clinic Near You

Who Is Running the Clinical Trial?

South Rampart Pharma, LLC

Lead Sponsor

Trials
1
Recruited
60+

References

The analgesic activity of biphalin and its analog AM 94 in rats. [2013]
Mu opioid antagonist properties of a cyclic somatostatin octapeptide in vivo: identification of mu receptor-related functions. [2013]
Intrathecal opioids block a spinal action of substance P in mice: functional importance of both mu- and delta-receptors. [2019]
Antinociceptive profile of potent opioid peptide AM94, a fluorinated analogue of biphalin with non-hydrazine linker. [2013]
Morphine (intracerebroventricular) activates spinal systems to inhibit behavior induced by putative pain neurotransmitters. [2013]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security